The Journal of allergy and clinical immunology · 2025
Late effects after hematopoietic stem cell transplantation in patients with HLH: A Histiocyte Society, PDWP, IEWP, and TCWP EBMT Study.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ramme Kim, Horne AnnaCarin, Beutel Karin, Galimard Jacques-Emmanuel, Alahmari Ali Abdallah, Ottaviano Giorgio, Moshous Despina, Kansoy Savas, Nademi Zohreh, Faraci Maura, Sundin Mikael, Fagioli Franca, Albert Michael H, Sedlacek Petr, Bertrand Yves, Locatelli Franco, Paillard Catherine, Mellgren Karin, Müller Ingo, Greil Johann, Balduzzi Adriana, Slatter Mary, Dalissier Arnaud, Kalwak Krzysztof, Lankester Arjan, Neven Benedicte, Baker K Scott, Rao Kanchan, Corbacioglu Selim
Аннотация
BACKGROUND: Hematopoietic stem cell transplantation (HCT) is the only curative treatment in primary hemophagocytic lymphohistiocytosis (pHLH). However, HCT is associated with a wide range of late effects (LEs).
OBJECTIVE: We sought to characterize the long-term outcome and LEs following HCT in pHLH.
METHODS: A total of 274 children with pHLH from the European Society for Blood and Marrow Transplantation registry who underwent allogeneic HCT between 2004 and 2015 were included. Multivariable logistic regression models were used to evaluate the adjusted impact of baseline variables on central nervous system and hormonal LEs, respectively.
RESULTS: A broad spectrum of LEs was identified, with neurologic (31%) and hormonal (34.8%) complications being the most prevalent. Chemotherapy (HLH-1994/HLH-2004) before HCT was identified as a significant risk factor for endocrinological LEs (P = .03), highlighting a novel aspect not previously reported. The presence of neurologic abnormality at diagnosis was an independent risk factor for neurologic LEs (P < .001) as was incomplete remission status at the time of HCT (P = .04).
CONCLUSIONS: HCT has significantly improved survival in patients with pHLH. However, survivors still face significant risks of LEs.
OBJECTIVE: We sought to characterize the long-term outcome and LEs following HCT in pHLH.
METHODS: A total of 274 children with pHLH from the European Society for Blood and Marrow Transplantation registry who underwent allogeneic HCT between 2004 and 2015 were included. Multivariable logistic regression models were used to evaluate the adjusted impact of baseline variables on central nervous system and hormonal LEs, respectively.
RESULTS: A broad spectrum of LEs was identified, with neurologic (31%) and hormonal (34.8%) complications being the most prevalent. Chemotherapy (HLH-1994/HLH-2004) before HCT was identified as a significant risk factor for endocrinological LEs (P = .03), highlighting a novel aspect not previously reported. The presence of neurologic abnormality at diagnosis was an independent risk factor for neurologic LEs (P < .001) as was incomplete remission status at the time of HCT (P = .04).
CONCLUSIONS: HCT has significantly improved survival in patients with pHLH. However, survivors still face significant risks of LEs.